机构：[1]School of Basic Medicine, Shanghai University of Medicine and Health Sciences, Shanghai, 201318, People’sRepublic of China[2]Department of Pathology, Renmin Hospital of Wuhan University, Wuhan, 430060, HubeiProvicne, People’s Republic of China[3]Pathology Center, Shanghai General Hospital/Faculty of Basic Medicine,School of Medicine, Shanghai Jiao Tong University, Shanghai, 200025, People’s Republic of China[4]SecondDepartment of Neurosurgery, The First Affiliated Hospital of Kunming Medical University, Kunming, 650032, YunnanProvince, People’s Republic of China外科科室神经外科神经外一科（神经外科）昆明医科大学附属第一医院[5]School of Clinical Medicine, Shanghai University of Medicine and HealthSciences, Shanghai, 201318, People’s Republic of China
Overlap in morphologic features between malignant and benign myogenic tumors, such as leiomyosarcoma (LMS) vs. leiomyoma as well as rhabdomyosarcoma (RMS) vs. rhabdomyoma, often makes differential diagnosis difficult and challenging. Here the expressions of Enhancer of Zeste Homolog 2 (EZH2), Suppressor of Zeste 12 (SUZ12), retinoblastoma protein associated protein 46 (RbAp46), Embryonic Ectoderm Development (EED) and ki-67 protein were detected by immunohistochemistry to evaluate their values in differential diagnosis. The expression of EZH2 mRNA was investigated by analyzing the Gene Expression Omnibus Datasets. The results demonstrated that EZH2 protein was detected in 81.25% (26/32) of LMS and 70.58% (36/51) of RMS, whereas none of leiomyoma (n = 16), rhabdomyoma (n = 15) and normal tissues (n = 31) showed positive immunostaining (p < 0.05). EZH2 protein was found to have a sensitivity of 91.30% and specificity of 100% in distinguishing well-differentiated LMS from cellular leiomyoma, and a sensitivity of 92.86% and specificity of 100% in distinguishing well-differentiated embryonal rhabdomyosarcoma (ERMS) from fetal rhabdomyoma. Besides, the expression of EZH2 mRNA was higher in LMS and RMS than in benign tumors (p < 0.05). The expressions of SUZ12 and RbAp46 protein were higher in RMS than in rhabdomyoma (p < 0.05). Conclusively, the high expression of EZH2 is a promising marker in distinguishing well-differentiated LMS from cellular leiomyoma, or well-differentiated ERMS from fetal rhabdomyoma, and the upregulation of EZH2 protein expression may occur at transcriptional level.
基金：
National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81602535, 81760223]; Shanghai Municipal Commission of Health and Family Planning [201740161]; Science and Technology Commission of Shanghai MunicipalityScience & Technology Commission of Shanghai Municipality (STCSM) [15ZR1421800]; Natural Science Foundation of Yunnan ProvinceNatural Science Foundation of Yunnan Province [FB2016121]
第一作者机构：[1]School of Basic Medicine, Shanghai University of Medicine and Health Sciences, Shanghai, 201318, People’sRepublic of China
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Zhang Ning,Zeng Zhi,Li Shaobo,et al.High expression of EZH2 as a marker for the differential diagnosis of malignant and benign myogenic tumors[J].SCIENTIFIC REPORTS.2018,8:doi:10.1038/s41598-018-30648-7.
APA：
Zhang, Ning,Zeng, Zhi,Li, Shaobo,Wang, Fei&Huang, Peng.(2018).High expression of EZH2 as a marker for the differential diagnosis of malignant and benign myogenic tumors.SCIENTIFIC REPORTS,8,
MLA：
Zhang, Ning,et al."High expression of EZH2 as a marker for the differential diagnosis of malignant and benign myogenic tumors".SCIENTIFIC REPORTS 8.(2018)
